Table 2. Clinical Outcomes.
Clinical Outcomes | Group, No. (%) | Difference, Mean (95% CI) | P Value | |
---|---|---|---|---|
Bevacizumab (n = 1131) | Control (n = 117) | |||
Follow-up time, mo | ||||
Mean | 40 | 58 | −18 (−24 to −13) | <.001a |
Median (range) | 34 (3 to 117) | 61 (3 to 130) | ||
Enucleation | 15 (1) | 3 (3) | NA | .44 |
Snellen visual acuity | ||||
No. | 1116 | 114 | NA | .002a |
20/20 to 20/40 | 419 (37) | 31 (27) | ||
20/50 to 20/150 | 299 (27) | 24 (21) | ||
20/200 or worse | 398 (36) | 59 (52) | ||
Visual acuity (Snellen) | ||||
Median | 20/70 | 20/200 | NA | NA |
Mean (range) | 20/200 (20/20 to NLP) | CF (20/20 to NLP) | ||
Visual acuity (logMAR) | ||||
Median | 0.54 | 1.30 | −0.49 (−0.71 to −021) | <.001a,b |
Mean (range) | 1.02 (0.00 to 5.00) | 1.53 (0.00 to 5.00) | ||
Lines of visual acuity loss at last follow-up date | ||||
Median | 2 | 5 | −1 (−2 to 0) | .01a,b |
Mean (range) | 4 (0 to 14) | 5 (0 to 14) | ||
Tumor features | ||||
Tumor basal diameter, mm | ||||
Mean | 10.5 | 9.9 | 0.7 (−0.1 to 1.4) | .09 |
Median (range) | 10.0 (1.0 to 20.0) | 10.0 (2.0 to 20.0) | ||
Tumor thickness, mm | ||||
Mean | 2.6 | 2.5 | 0.2 (−0.1 to 0.5) | .23 |
Median (range) | 2.2 (0.5 to 12.0) | 2.0 (1.0 to 9.8) | ||
Recurrence of tumor | 23 (2) | 5 (4) | NA | .18 |
Time to recurrence, mo | ||||
Mean | 28 | 62 | −34 (−55 to −14) | .01a |
Median (range) | 20 (4 to 80) | 67 (27 to 92) | ||
Radiation complications | ||||
Cystoid macular edema by OCT | 413 (37) | 58 (50) | NA | .01a |
Time to onset of cystoid macular edema, mo | ||||
Mean | 27 | 27 | 0 (−6 to 5) | .84 |
Median (range) | 22 (3 to 98) | 20 (3 to 104) | ||
Radiation maculopathy | 431 (38) | 59 (50) | NA | .01a |
Time to radiation maculopathy, mo | ||||
Mean | 29 | 27 | 1 (−3 to 6) | .58 |
Median (range) | 24 (4 to 114) | 20 (4 to 68) | ||
Radiation papillopathy | 197 (17) | 31 (27) | NA | .02a |
Time to radiation papillopathy, mo | ||||
Mean | 30 | 27 | 2 (−4 to 8) | .47 |
Median (range) | 27 (2 to 93) | 21 (4 to 72) | ||
Nonproliferative radiation retinopathy | 269 (24) | 40 (34) | NA | .01a |
Time to nonproliferative radiation retinopathy, mo | ||||
Mean | 28 | 27 | 0 (−5 to 6) | .88 |
Median (range) | 24 (4 to 97) | 21 (4 to 72) | ||
Proliferative radiation retinopathy | 7 (1) | 7 (6) | NA | <.001a |
Time to proliferative radiation retinopathy, mo | ||||
Mean | 33 | 35 | −1 (−25 to 22) | .92 |
Median (range) | 36 (3 to 55) | 26 (11 to 72) | ||
Retinal vessel occlusion | ||||
Branch retinal vein occlusion | 310 (27) | 42 (36) | NA | .43 |
Central retinal vein occlusion | 7 (1) | 0 | ||
Branch retinal artery occlusion | 8 (1) | 0 | ||
Time to retinal vessel occlusion, mo | ||||
Mean | 27 | 33 | −6 (−12 to 0) | .07 |
Median (range) | 23 (3 to 103) | 35 (4 to 88) | ||
Neovascularization of the iris | 31 (3) | 7 (6) | NA | .05 |
Time to neovascularization of the iris, mo | ||||
Mean | 33 | 29 | 4 (−13 to 21) | .66 |
Median (range) | 33 (4 to 69) | 22 (11 to 75) | ||
Neovascular glaucoma | 32 (3) | 7 (6) | NA | .06 |
Time to neovascular glaucoma, mo | ||||
Mean | 38 | 33 | 5 (−15 to 25) | .63 |
Median (range) | 34 (4 to 96) | 22 (11 to 86) | ||
Cataract | 302 (27) | 45 (38) | NA | .01a |
Time to cataract, mo | ||||
Mean | 27 | 27 | −1 (−7 to 6) | .81 |
Median (range) | 21 (2 to 138) | 24 (2 to 79) | ||
Scleral necrosis | 12 (1) | 3 (3) | NA | .39 |
Time to scleral necrosis, mo | ||||
Mean | 40 | 34 | 5 (−23 to 34) | .70 |
Median (range) | 35 (8 to 81) | 33 (10 to 60) |
Abbreviations: CF, counting fingers; NLP, no light perception; NA, not applicable; OCT, optical coherence tomography.
Significant P value
By Mann-Whitney U test.